Docetaxel Does Not Improve OS, mPFS in Non-Metastatic Prostate Cancer - Cancer Therapy Advisor

Adding docetaxel to standard care improved failure-free survival and progression-free survival (PFS) but not overall survival, metastatic PFS, or prostate cancer-specific survival.

Adding docetaxel to standard care does not improve metastasis-free survival or overall survival (OS) for patients with non-metastatic prostate cancer, according to results from the STAMPEDE trial pub… [+2905 chars]

full article...